Zack's bio-tech analyst Jason Napadano says it's a "BUY" with a price target of .20.
Buy a few shares for under a nickle and hold them for six months.
Read the recent Yahoo news.
Lots of potential for less than a nickle.
Napadano say's it's a buy with a .20 price target.
MANF + Diabetes + Novartis = Tremendous Potential
You'll soon regret not having bought more shares of AMBS. Maybe not today or tomorrow but soon and for the rest of your life.
Best opportunity for substantial profits in the market.
Buy a few shares of "AMBS" today for less than a nickle a share. Hold them until the company up-lists to the NASDAQ next year and thank me then.
The rocket is on the launching pad and the fuel is being added.
This is overdue for a run towards .20.
Zack's bio-tech analyst, Jason Napadano, recently placed a buy rating on AMBS with a .20 price target. It's the first time he's placed a buy rating on a penny stock.
Read his valuation article about Amarantus on SeekingAlpha.
If so then go buy a few shares of "AMBS" and hold them for a year. Read the recent Yahoo news.
Follow the company on Twitter: @AmarantusBio ... 8,587 followers